Biopharma manufacturing company Repligen Corporation (NASDAQ: RGEN) will be announcing earnings results tomorrow morning. Here’s what to look for.
Repligen met analysts’ revenue expectations last quarter, reporting revenues of $167.5 million, flat year on year. It was a satisfactory quarter for the company, with a solid beat of analysts’ organic revenue estimates.
Is Repligen a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Repligen’s revenue to grow 7.2% year on year to $164.3 million, a reversal from the 7.4% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.35 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Repligen has missed Wall Street’s revenue estimates four times over the last two years.
Looking at Repligen’s peers in the life sciences tools & services segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Medpace delivered year-on-year revenue growth of 9.3%, beating analysts’ expectations by 6%, and West Pharmaceutical Services reported flat revenue, topping estimates by 2%. Medpace traded down 2.1% following the results while West Pharmaceutical Services was also down 1.6%.
Read our full analysis of Medpace’s results here and West Pharmaceutical Services’s results here.
Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the life sciences tools & services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 5.6% on average over the last month. Repligen is up 15.5% during the same time and is heading into earnings with an average analyst price target of $187.60 (compared to the current share price of $146.97).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.
